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Abstract: The HMG-CoA reductase inhibitors (statins) are used extensively in the treatment 
of hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes. 
These secondary actions are known as pleiotropic effects. Our paper serves as a focused and 
updated discussion on the pleiotropy of statins and emphasizes the importance of randomized 
placebo-controlled trials to further elucidate this interesting phenomenon.
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Introduction
Statins are a mainstay in the treatment of hyperlipidemia and are used in the primary 
and secondary prevention of coronary artery disease.1,2 Recent studies have shown that 
statins also possess powerful pleiotropic effects that are independent of their cholesterol-
lowering properties, a fact that has piqued the interest of the medical community.
The pleiotropic effects of statins are attributed to several processes resulting from 
the inhibition of HMG-CoA reductase. The main effect of statins is the inhibition 
of cholesterol and isoprenoid synthesis, which ultimately results in upregulation of 
endothelial nitric oxide synthase, an enzyme responsible for vascular endothelial 
function, and thus improved pathophysiologic response.3,4 Additionally, antioxidant 
effects via the decreased production of NADPH oxidase leads to decreased amounts of 
reactive oxidant species in the circulation.3 Inflammatory markers such as C-reactive 
protein and nuclear factor-k B have also been shown to be reduced by statins, leading 
to the hypothesis that statins possess anti-inflammatory properties.5 Other proposed 
mechanisms include immunomodulation, normalization of sympathetic outflow, plaque 
stabilization, decreased activation of the blood coagulation cascade, and inhibition of 
platelet aggregation (Table 1).6
A wide range of disease processes have been linked to better outcomes when patients 
are treated with statins (Table 2). The following is a review of the current literature 
and recent studies regarding the potential therapeutic benefits and pleiotropic effects 
of statins (Table 3).
Cardiovascular disorders
Heart failure
Patients in the early or mild stages of heart failure have been shown to benefit 
from statins via their anti-inflammatory properties and enhancement of endothelial 
function.7,8 The CORONA (Controlled Rosuvastatin Multinational Trial in Heart International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Failure) trial,9 a retrospective study of 5011 patients, con-
cluded that those with high   sensitivity C-reactive protein 
.2 mg/L   receiving rosuvastatin 10 mg daily had a reduced 
incidence of the primary outcome (cardiovascular death, 
myocardial infarction or stroke, P = 0.024), coronary events 
(P = 0.017), all-cause mortality or worsening heart failure 
(P = 0.017), and a decreased number of hospitalizations for 
  cardiovascular   reasons (P , 0.001) or worsening heart fail-
ure (P = 0.004) compared to placebo. The benefit of reduced 
incidence of cardiovascular   hospitalization was also seen in 
a study by Kjeshkus et al10 of elderly systolic heart failure 
patients treated with rosuvastatin (P = 0.04).
Atrial fibrillation
Statins have been shown to prevent structural and electrical 
remodeling and blunt the development of atrial fibrillation 
in the setting of atrial tachycardia.11 Additionally, shortened 
intra-atrial conduction time, decreased duration of atrial 
fibrillation, and increased atrial effective refractory period 
have been shown to be the result of anti-inflammatory prop-
erties possessed by statins.12
Young-Xu et al13 prospectively evaluated 449 patients with 
stable coronary artery disease and no history of atrial fibril-
lation over five years, and found that statin users had a 59% 
decreased risk of developing atrial fibrillation (P , 0.01). 
Meanwhile, Kulik et al14 assessed the incidence of new-
onset atrial fibrillation in 29,088 patients after myocardial 
infarction or coronary revascularization, and found a 10% 
reduced risk in statin-treated patients (P = 0.0006). Siu et al15 
retrospectively studied 62 patients with lone persistent atrial 
fibrillation of at least three months’ duration who underwent 
successful external electrical cardioversion, and showed that 
statin use was associated with a significantly decreased risk 
of recurrence of atrial fibrillation (P = 0.032).
The incidence and duration of atrial fibrillation is also 
decreased by statins in postoperative cardiac patients. In a 
cohort of 140 patients without prior atrial fibrillation or statin 
use undergoing elective coronary artery bypass grafting, the 
incidence of new-onset atrial fibrillation was 14% versus 32% 
for the control group (P = 0.009), with a mean duration of single 
atrial fibrillation of 3.6 hours versus 5.7 hours (P , 0.01) dur-
ing the first seven postoperative days in those assigned to daily 
atorvastatin.16 Furthermore, a recent observational study using 
data from 64,679 patients enrolled in GRACE (Global Registry 
of Acute Coronary Events)17 showed that statin users hospital-
ized for acute coronary syndrome were not only at lower risk 
of developing inhospital atrial fibrillation (P , 0.0001), but 
also had a significantly decreased risk of developing ventricular 
arrhythmias, cardiac arrest, and/or death.
ventricular arrhythmias
Studies have shown a correlation between statin use 
and a decreased incidence of ventricular arrhythmias or   
Table 1 Proposed mechanisms of statin pleiotropy
•   Upregulation of endothelial nitric oxide synthase and improved 
pathophysiologic response, including inhibition of vasoconstriction  
and promotion of re-endothelialization
•   Antioxidant effects via the inhibition of nicotinamide adenine 
dinucleotide phosphate oxidase and thus reactive oxidant species
•   Anti-inflammatory properties, including reduction in C-reactive  
protein, interleukin 6, tumor necrosis factor alpha, and nuclear 
factor-k B levels
• Downregulation of cytokines and chemokines
•   Stabilization of atherosclerotic plaques and inhibition of plaque 
inflammation
• Decreased activation of the blood coagulation cascade
• Inhibition of platelet aggregation
• Normalization of sympathetic tract outflow
• Induction of autophagy and inhibition of angiogenesis in cancer cells
• Neuroprotection and support of blood–brain barrier function
Table 2 Overview of statin pleiotropy and medical disorders
System Disorder
Cardiology Heart failure 
Atrial fibrillation 
ventricular arrhythmias 
Acute coronary syndrome and  
percutaneous coronary intervention 
Aortic stenosis
Pulmonology Asthma 
Chronic obstructive lung disease
Hematology/oncology Prostate cancer 
Colon cancer 
Lung cancer 
Pancreatic cancer 
Renal cancer
Neurology Stroke 
Intracranial hemorrhage 
Multiple sclerosis 
Alzheimer’s disease 
Parkinson’s disease
Nephrology Glomerulonephritis 
Renal failure 
Renal transplantation 
Contrast-induced nephropathy
Rheumatology Rheumatoid arthritis 
Osteoarthritis 
Osteoporosis 
Systemic sclerosis
Miscellaneous venous thromboembolism 
Polycystic ovary syndrome 
Macular degeneration 
Influenza 
Infection and sepsisInternational Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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sudden cardiac death. Chiu et al18 assessed 281 patients 
with   ischemic cardiomyopathy undergoing implantable 
  cardioverter   defibrillator placement with subsequent 
  outpatient follow-up. Those who received statin therapy 
had a reduced incidence of ventricular arrhythmia requir-
ing use of the defibrillator (P = 0.01). The MADIT-II 
(Multicenter Automatic   Defibrillator Implantation 
Trial II) trial19 looked at 654 patients with ischemic 
  cardiomyopathy and implantable cardioverter defibrilla-
tor placement, and found a 35% risk reduction for sudden 
cardiac death or development of ventricular arrhythmia in 
patients taking statins (P , 0.01). The results observed 
may be due to   mechanisms similar to those seen in atrial 
  fibrillation, with plaque stabilization also protecting 
against ischemia-induced arrhythmias.
Percutaneous coronary intervention  
and acute coronary syndrome
Statin pleiotropy in patients undergoing percutaneous coro-
nary intervention has been well established. Via their ability 
to stabilize plaques and exert anti-inflammatory and anti-
thrombotic properties, statins increase coronary blood flow 
and microvascular myocardial perfusion.20 The ARMYDA 
(Atorvastatin for Reduction of Myocardial Damage during 
Angioplasty) trial,21 which looked at 153 statin-naïve patients 
with stable angina undergoing elective percutaneous coronary 
Table 3 Major trials and studies exhibiting statin pleiotropy
Trial/study Design Outcomes with statin treatment
Controlled Rosuvastatin Multinational  
Trial in Heart Failure (CORONA)7,9
5011 patients with heart failure,  
reduced left ventricular function, and  
ischemic heart disease randomly assigned  
to 10 mg/day rosuvastatin or placebo
Patients with NT-proBNP , 103 pmol/L had 35% 
reduction in atherothrombotic events or sudden death  
Patients with hs-CRP . 2 mg/L had better outcomes, 
decreased all-cause mortality and coronary events, less 
hospitalizations
Global Registry of Acute Coronary  
events (GRACe)17
64,679 patients hospitalized for ACS  
in 1999–2007 were prospectively analyzed  
in an observational study
Patients taking statins prior to hospital admission had 
a significantly lower risk of atrial fibrillation, VT/VF, 
cardiac arrest, and death
Multicenter Automatic Defibrillator  
Implantation Trial II (MADIT-II)19
654 patients receiving an ICD were  
analyzed based on the percentage of  
days statins were taken during follow-up
$90% statin usage was associated with a reduced risk 
of vT/vF or cardiac death
Efficacy of high-dose atorvastatin  
loading before primary percutaneous  
coronary intervention in ST-segment  
elevation myocardial infarction: The 
STATIN STeMI trial20
171 STeMI patients randomized to 600 mg  
Plavix® plus either 80 mg or 10 mg  
atorvastatin pre-PCI, with all patients  
treated with 10 mg atorvastatin post-PCI 
High-dose atorvastatin pre-PCI was associated 
with immediate improvement of coronary flow and 
microvascular myocardial perfusion when compared 
with low-dose atorvastatin
Atorvastatin for Reduction of  
Myocardial Damage during  
Angioplasty trial (ARMYDA)21
153 statin-naïve patients with chronic stable  
angina undergoing elective PCI randomized  
to atorvastatin or placebo seven days prior  
to intervention
Significant reduction in procedural myocardial injury
Pravastatin or Atorvastatin evaluation  
and Infection Therapy-Thrombolysis  
In Myocardial Infarction 22 trial  
(PROve IT-TIMI 22)24
3745 ACS patients randomized to  
either 40 mg pravastatin or 80 mg  
atorvastatin daily
High-dose statin therapy superior in aggressive 
reduction of both LDL-C and CRP levels, leading 
to lower risk of recurrent myocardial infarction or 
vascular death
Pravastatin or Atorvastatin evaluation  
and Infection Therapy-Thrombolysis  
In Myocardial Infarction 22  
[PROve IT-TIMI 22] Substudy  
(PCI-PROve IT)25
2868 ACS patients who underwent PCI  
prior to enrollment in PROve IT-TIMI 22,  
which randomized patients to 80 mg  
atorvastatin or 40 mg pravastatin daily
Reduction in major adverse cardiovascular events, as 
well as target and nontarget vessel revascularization 
with intensive statin therapy
Efficacy of atorvastatin reload in patients  
on chronic statin therapy undergoing 
percutaneous coronary intervention:  
results of the ARMYDA-ReCAPTURe  
randomized trial26
383 long-term statin users with stable angina  
or NSTeMI undergoing PCI were randomized  
to atorvastatin reload or placebo pre-PCI,  
with all patients treated with  
atorvastatin post-PCI
Decreased 30-day incidence of major adverse 
cardiovascular events, as well as postprocedural 
myocardial injury, in patients receiving high-dose  
pre-PCI atorvastatin reload
Justification for the Use of statins in  
Prevention: an Intervention Trial  
evaluating Rosuvastatin (JUPITeR)50
17,802 patients with normal LDL-C and  
elevated CRP randomly assigned to  
20 mg/day rosuvastatin or placebo
Reduced the incidence of stroke by more than 50%; 
reduction in nonfatal MI and cardiovascular death
Abbreviations: NT-proBNP, N-terminal fragment brain natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; ACS, acute coronary syndrome; vT, ventricular 
tachycardia;  VF,  ventricular  fibrillation;  ICD,  implantable  cardioverter  defibrillator;  STEMI,  ST-segment  elevation  myocardial  infarction;  PCI,  percutaneous  coronary 
intervention; LDL-C, low density lipoprotein cholesterol; NSTeMI, non-ST-segment elevation myocardial infarction; MI, myocardial infarction.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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intervention, found a significantly reduced risk of myocardial 
injury in patients assigned to 40 mg of atorvastatin daily 
for seven days prior to percutaneous coronary intervention, 
with similar results reported in other randomized trials.22,23 
Additionally, recent studies suggest an increased benefit with 
high-dose therapy as opposed to conservative regimens.24 
Gibson et al25 assessed the incidence of the primary composite 
endpoint (all-cause mortality, myocardial infarction, unstable 
angina leading to hospitalization, 30-day revascularization, 
or stroke), target vessel revascularization, and nontarget 
vessel revascularization among 2868 patients undergoing 
percutaneous coronary intervention in the setting of acute 
coronary syndrome. Those treated daily with 80 mg of 
atorvastatin had a decreased incidence of the primary com-
posite endpoint (21.5% versus 26.5%, P = 0.002) and target 
vessel revascularization (11.4% versus 15.4%, P = 0.001) 
compared with patients treated with 40 mg of pravastatin. 
Furthermore, patients on chronic statin therapy suffering from 
stable angina or acute non-ST-segment elevation myocardial 
infarction benefit from reloading with statins before percu-
taneous coronary intervention, having a 50% reduced risk 
of major adverse cardiac events (cardiac death, myocardial 
infarction, or unplanned revascularization) after intervention 
(P = 0.039).26
Aortic stenosis
It has been postulated that the anti-inflammatory effects of 
statins may help in reducing the progression of aortic stenosis. 
A retrospective study27 of 174 patients with mild to moderate 
aortic stenosis, of whom 57 were on statins, demonstrated a 
decrease in the aortic valve area of 0.06 cm²/year in the statin 
treatment group compared with 0.11 cm²/year in the non-
statin group (P = 0.03) at the 21-month follow-up. Another 
retrospective study28 of 180 patients with mild aortic stenosis 
and on statin treatment showed a reduction in the increase in 
the peak systolic gradient across the aortic valve over three 
years (P = 0.009).
A four-year prospective trial by Bellamy et al29 of 
156 patients taking either simvastatin or lovastatin demon-
strated that statin users had a slower reduction of aortic valve 
area of -0.04 cm²/year versus 0.09 cm²/year in the placebo 
group (P , 0.01). Another prospective study called RAAVE 
(Rosuvastatin Affecting Aortic Valve Endothelium)30 com-
pared the effects of rosuvastatin versus placebo in 121 patients 
with moderate to severe asymptomatic aortic stenosis. At the 
18-month follow-up, researchers found a decrease in aortic 
valve area of 0.05 cm² in the   rosuvastatin group, compared 
with 0.10 cm² in the placebo group (P = 0.041, Table 4).
Pulmonary disorders
Asthma
Statins may play a protective role in asthma patients by 
curbing inflammation and airway remodeling. A recent 
study31 assessed 70 asthmatic patients at baseline and two 
months after beginning statin therapy. Researchers found a 
decrease in rescue inhaler use from nine to five times per 
week (P , 0.0001), increased peak flow from 301 L/min 
two months prior to 335 L/min two months after starting 
therapy (P , 0.0001), and an increase in patients classified 
as having “mild” disease, with a concurrent decrease in 
“moderate-to-severe” classifications. Additionally, studies 
have shown that adult asthmatics receiving statin therapy 
have a 30% risk reduction for hospitalizations and emergency 
department visits related to their disease (P , 0.001).32
Chronic obstructive lung disease
Blamoun et al33 retrospectively assessed the incidence of 
chronic obstructive pulmonary disease exacerbations and 
intubations in 185 statin users with established obstructive 
lung disease. At one year, patients not taking statins were 
Table 4 Pleiotropic effects of statins in cardiovascular disorders
Heart failure7–10 •   ↓ risk of coronary events and 
cardiovascular death
• ↓ all-cause mortality
•   ↓ hospitalizations for cardiovascular 
reasons or worsening heart failure
•   Prevent further decompensation of cardiac 
function
Atrial fibrillation13–17 • ↓ duration of atrial fibrillation
•   59% ↓ incidence in stable coronary artery 
disease
•   10% ↓ incidence after myocardial infarction 
or coronary revascularization
• ↓ recurrence after electric cardioversion
•   ↓ incidence after acute coronary syndrome
•   ↓ incidence and duration in postoperative 
cardiac patients
ventricular  
arrhythmias18,19
•   ↓ incidence of ICD shocks and 35%  
↓ risk of sudden cardiac death in patients 
with ICD and ischemic cardiomyopathy
Percutaneous coronary 
intervention and acute  
coronary syndrome21–26
•   Significantly reduced risk of myocardial 
injury in elective PCI in statin-naïve patients
•   50% ↓ risk of major adverse cardiac events 
in statin users reloaded with statin prior 
to PCI
•   Superior concomitant reduction in LDL-C 
and CRP with high-dose statin therapy
Aortic stenosis27–30 • Significantly slower reduction of AV area
• Slower increase of Av peak systolic gradient
Abbreviations:  ICD,  implantable  cardioverter  defibrillator;  PCI,  percutaneous 
coronary intervention; LDL-C, low-density lipoprotein cholesterol; CRP, C-reactive 
protein; Av, aortic valve.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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more likely to have suffered an exacerbation (P , 0.0001) 
or have required intubation (P , 0.0001) compared with the 
treatment group. Statins have also been shown to decrease 
90-day mortality in patients hospitalized with emphysema-
tous exacerbations34 and are useful in preservation of lung 
function in elderly patients with a history of smoking.35,36
Cancers
Prostate cancer
Studies have shown that statins induce autophagy and cell 
death in prostate cancer cells while causing no hindrance to 
normal cells.37 A retrospective analysis of CaPSURE (Cancer 
of the Prostate Strategic Urologic Research Endeavor),38 
which included 7042 men who underwent radical prostate-
ctomy or radiotherapy for prostate cancer, showed a 65% 
reduction in all-cause mortality after radical prostatectomy 
and a 41% reduction after radiotherapy with concomitant use 
of statins. A second study demonstrated improved freedom 
from biochemical failure and salvage androgen deprivation 
therapy, as well as improved relapse-free survival rates in 
statin users who underwent radiotherapy.39 Furthermore, 
patients undergoing radical prostactectomy placed on preop-
erative simvastatin have a 69% reduced risk of intratumoral 
inflammation, a complication that may lead to prostate cancer 
progression.40
Colon cancer
Studies have shown that statins inhibit the progression 
of colon cancer and attenuate tumor burden by inducing 
apoptosis,41–43 inhibiting angiogenesis,41 and decreasing the 
production of proinflammatory cytokines. A case-control 
study by Poynter et al44 found that patients treated with at 
least five years of statin therapy had a 50% reduced risk of 
colorectal cancer, adding to prior reports of lower rates of 
Stage IV carcinomas in statin users.45 Additionally, patients 
with a history of adenomatous colon polyps who were on 
statins had smaller polyp size, a reduced number of polyps, 
and reduced incidence of pathologic progression or recurrent 
polyps on 3–5-year colonoscopy follow-up,46 suggesting 
that statins may play a preventive role in the development 
of colorectal cancer.
Lung, pancreatic, and renal cancer
Khurana et al47–49 performed a series of retrospective nested 
case-control studies using the Veterans Affairs database. 
Patients who used statins for at least six months had a 55% 
(P , 0.01) decreased incidence of lung cancer and a 67% 
(P , 0.01) reduced risk of developing pancreatic cancer, 
while patients on statin therapy for longer than four years had 
an 80% (P , 0.01) decreased risk in developing pancreatic 
cancer. The authors concluded that statins may also play a 
protective role in the development of renal cell carcinoma 
(Table 5).
Neurological disorders
Stroke and intracranial hemorrhage
Statins have been shown to be beneficial in primary and 
secondary stroke prevention,50 preventing   ischemia and 
hemorrhage by increasing cerebral vasomotor   reactivity 
and decreasing vasospasm.51–53 A meta-analysis of randomized 
trials that included 165,792 patients found statin users to have 
a 21% reduced risk of stroke (P = 0.009), while patients 
with prior stroke had a 16% reduced risk of recurrence 
(P = 0.03).54 Similar effects have been observed in patients 
with intracranial hemorrhage. Naval et al55 retrospectively 
looked at 125 patients with intracranial hemorrhage unrelated 
to trauma or an underlying lesion. Statin use was associated 
with decreased mortality and a 12-fold increase in rate of 
survival (P = 0.05). Furthermore, a meta-analysis56 of ran-
domized trials of patients with aneurysmal subarachnoid 
hemorrhage found that those who were started on statin 
therapy at the time of the event had a 27% reduced risk of 
vasospasm, a 62% reduction in delayed ischemic events, and 
an 82% reduction in mortality.
Multiple sclerosis
Statins have synergistic effects when used in combination 
with conventional multiple sclerosis drugs and may possess 
reparative properties.57,58 It is hypothesized that their ability 
to reduce the amount of lymphocytes and monocytes crossing 
the blood–brain barrier decreases the amount of perivascular 
infiltrates that fuel demyelination.59,60 Vollmer et al61 
prospectively studied 30 patients with relapsing-remitting 
multiple sclerosis and reported a 44% decrease (P , 0.0001) 
Table 5 Pleiotropic effects of statins in malignancies
Prostate cancer38–40 • ↓ all-cause mortality
• ↑ relapse-free survival
• ↓ risk of intratumoral inflammation
•   ↓ biochemical failure and androgen deprivation 
therapy
Colon cancer44–46 • 50% ↓ risk of colorectal cancer after 5 years
• ↓ rate of stage Iv carcinomas
• ↓ colon polyp size, number, and progression rate
Lung cancer47 • 50% ↓ incidence after 6 months of therapy
Pancreatic cancer48 •   67% ↓ incidence after 6 months, 80% ↓ after 
four yearsInternational Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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in the number and a 41% decrease (P , 0.0018) in the   volume 
of gadolinium-enhancing brain lesions after six months 
of treatment with 80 mg of simvastatin daily. Paul et al62 
verified these findings, showing that patients treated with 
high-dose atorvastatin had a significantly decreased number 
(P , 0.003) and size (P , 0.008) of lesions on magnetic 
resonance imaging after 6–9 months of therapy.
Alzheimer’s disease
By impairing production of beta-amyloid proteins and 
apolipoprotein E and exerting anti-inflammatory effects,63 
statins are proposed to decrease the amount of tau fibril-
lization in the pathophysiologic process of Alzheimer’s 
disease.64 A recent study by Li et al65 of 3099 elderly patients 
reported a 38% reduction in development of Alzheimer’s 
disease in those who began taking statins before the age 
of 80 years. A second study by Rosenberg et al66 found 
a significant reduction in the progression of dementia in 
Alzheimer’s patients taking statins when compared with 
control subjects (P = 0.03).
Parkinson’s disease
Using a mouse model of Parkinson’s disease, Ghosh et al67 
observed protection of dopaminergic neurons, striatal 
neurotransmitter normalization, and stabilization of motor 
function in mice treated with simvastatin or pravastatin. 
Analysis of the US Veterans’ Affairs database showed a 54% 
reduced incidence of dementia (P , 0.0001) and a 49% reduc-
tion in the incidence of newly diagnosed   Parkinson’s disease 
in individuals who were taking simvastatin (P , 0.0001).68 
Additionally, Wahner et al69 found that patients who were on 
statin therapy for at least five years had a 63% reduction in 
the incidence of Parkinson’s disease.
Renovascular disorders
Glomerulonephritis and renal failure
By inhibiting signaling pathways that lead to renal inflam-
mation, glomerular scarring, and mesangial proliferation,70 
statins reduce the systemic production and renal infiltration 
of T cells, T-helper cells, macrophages, and neutrophils.71 
Ozsoy et al72 studied 31 patients with established glomerulo-
nephritis and proteinuria who were on angiotensin-converting 
enzyme inhibitor therapy. Adding atorvastatin to their 
medical regimen conferred a 22% reduction in proteinuria 
after six weeks of therapy (P = 0.005). The benefits of statin 
therapy have also been observed in hemodialysis patients, 
who were shown to require significantly lower erythropoietin 
administration (P , 0.05) for renal failure-associated anemia 
compared with their untreated counterparts.73
Renal transplantation
Of particular interest are recent studies that have shown 
statin pleiotropy in patients who have undergone renal 
transplantation. Pazik et al74 looked at patients with post-
transplant glomerulonephritis and found that maintenance 
immunosuppression with steroid infusions, alkylating 
agents, or antiproliferatives did not prolong graft survival. 
However, patients who had a statin added to their medical 
regimen had a 63% reduced risk (P , 0.02) of graft loss, and 
when combined with renin-angiotensin-aldosterone system 
inhibitors, the reduction increased to 76% (P , 0.008).
Contrast-induced nephropathy
The antioxidant and vascular effects of statins are thought to 
attenuate the development of contrast-induced nephropathy, 
a serious complication of radiographic and diagnostic pro-
cedures that results from decreased renal medullary blood 
flow and toxic insult to the renal tubules.75 Khanal et al76 
looked at 29,409 patients who underwent percutaneous 
coronary intervention and found that chronic statin therapy 
prior to intervention was associated with a lower risk of 
contrast-induced nephropathy (P , 0.0001) or renal damage 
requiring dialysis therapy (P = 0.03). Similar findings were 
reported by Patti et al,77 who observed 434 patients under-
going percutaneous coronary intervention and found that 
preprocedural statin therapy resulted in a reduced incidence 
of contrast-induced nephropathy (P , 0.0001) and a greater 
postprocedure creatinine clearance compared with placebo 
(P , 0.0001).
Rheumatologic disorders
Rheumatoid arthritis
Via the inhibition and downregulation of proinflammatory 
cytokines and chemokines,78,79 statins have been shown to 
decrease serum C-reactive protein (P = 0.025) and tumor 
necrosis factor-alpha levels (P = 0.012) significantly in 
rheumatoid arthritis patients while improving endothe-
lial function.80 Recently, Amital et al81 reviewed a large 
health maintenance organization database and looked at 
the incidence of newly diagnosed rheumatoid arthritis 
over a 10-year period. Statin users had a 40% reduced 
risk (P , 0.001) of developing rheumatoid arthritis, and 
their protective value was greater the younger the age of 
the patient (P , 0.001).International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Osteoporosis
Statins inhibit osteoclast bone resorption and   stimulate the 
production of specific proteins involved in the development of 
bone and cartilage,82,83 thus emerging as a possible therapeutic 
option for patients with osteoporosis. Tanriverdi et al84 
followed 120 hypercholesterolemic   postmenopausal women 
with osteoporosis or osteopenia over a six-month period. 
Women treated with risedronate and atorvastatin had a two-
fold increase in bone mineral density at the lumbar spine com-
pared with women treated with risedronate alone (P , 0.05). 
A meta-analysis by Hatzigeorgiou et al85 revealed that 
patients taking statins had a 40% reduction in hip fractures 
and improved hip bone mineral density, and statin therapy 
has also been linked to increased bone mineral density at the 
femur and femoral neck (P , 0.05).86
Systemic sclerosis
Statins are hypothesized to reduce endothelial injury and 
inhibit defective vasculogenesis and vascular fibrosis in 
patients with systemic sclerosis.87,88 Kuwana et al89 treated 
eight systemic sclerosis patients with 10 mg of atorvastatin 
daily for a total of 24 months and found a reduction in flairs 
of Raynaud’s phenomenon, decreased activation of angio-
genic factors, and reduced levels of vascular endothelial 
activation and injury markers. A separate randomized trial 
by Abou-Raya et al90 of 84 patients with systemic sclerosis 
also showed the benefit of statin therapy, as patients treated 
with 40 mg of atorvastatin daily developed an average of 1.6 
new digital ulcers over a four-month treatment period versus 
2.5 in the placebo group (P = 0.003).
Miscellaneous disorders
venous thromboembolism
Circulating lipid molecules appear to affect vascular endothe-
lial and platelet function and may act as procoagulants, thus 
lipid-lowering with statins may protect against development 
of venous thromboembolism.91 A recent meta-analysis92 of 
nearly one million patients from one randomized and nine 
observational trials who were on statin therapy for cardio-
vascular risk prevention revealed a 32% decreased risk of 
venous thromboembolism (P , 0.05), a 41% decreased risk 
of deep vein thrombosis (P , 0.05), and a 30% decreased risk 
of pulmonary embolism (P , 0.05). Furthermore, evidence 
suggests that statins may be of particular benefit in cancer 
patients, in whom venous thromboembolism and pulmo-
nary embolism are serious sequelae. Khemasuwan et al93 
retrospectively studied 740 patients with solid organ tumors 
who were hospitalized and placed on a statin, and found 
a 67% decreased risk of venous thromboembolism within 
two months of admission in statin users (P , 0.001).
Polycystic ovary syndrome
A reduction in insulin receptor maturation and inhibition 
of thecal interstitial cell proliferation are hypothesized 
to be the pleiotropic mechanisms of statins observed in 
females suffering from polycystic ovary syndrome.94,95 
Sathyapalan et al96 studied 40 statin-naïve patients who 
were placed on 12 weeks of atorvastatin therapy and found 
significant reductions in testosterone (P , 0.01), free 
androgen index (testosterone/sex hormone binding globulin, 
P , 0.01), and insulin resistance as measured by the homeo-
stasis model   assessment for insulin resistance. A study by 
Banaszewska et al97 compared 48 polycystic ovary syndrome 
patients on oral contraceptive treatment with patients on oral 
contraceptive treatment plus simvastatin, and found that 
adjuvant statin therapy was associated with an additional 
12% reduction in total testosterone (P , 0.004), a 23% 
reduction in free testosterone (P = 0.006), a 3.4% decreased 
incidence in hirsutism (P = 0.02), and a 39% reduction in 
C-reactive protein level (P = 0.006) compared with those on 
oral contraceptive treatment alone.
Macular degeneration
Statin use has been linked to a 67% reduction in drusen 
formation,98 which deprives certain areas of the eye of oxy-
gen and nutrients and is associated with the onset of macular 
degeneration.   Choroidal neovascularization, an early symptom 
of age-related macular degeneration, has also been shown 
to be inhibited by statins in vitro.99 A retrospective study 
by Wilson et al100 of 326 patients with age-related macular 
degeneration reported a 49% reduction in the rate of choroidal 
neovascularization in statin-treated patients (P = 0.01), while 
a case-control study by McGwin et al101 found a 70% risk 
reduction in newly-diagnosed macular degeneration amongst 
statin users.
Influenza
Recent data suggest that statins may confer protection 
against infectious diseases, including the influenza virus. 
Kwong et al102 assessed the effects of statin use on hospital-
ization rates and mortality during the influenza season over 
a 10-year period using a population-based cohort study of 
2.2 million patients. Researchers found an 8% reduced risk 
of pneumonia hospitalization and a 16% reduction in 30-day International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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pneumonia mortality. A separate matched cohort study of 
76,232 patients by Frost et al103 found a 40% reduction in the 
risk of pneumonia or influenza-related death in moderate-
dose statin users, and a recent study104 presented at the 2010 
Infectious Disease Society of America annual meeting 
showed a 54% reduced risk of death amongst statin users 
hospitalized for influenza.
Infection and sepsis
A recent meta-analysis of 20 studies analyzed the effects of 
statins on mortality from infection and sepsis. Statin therapy 
was associated with a 39% reduction in 30-day mortality, 
a 62% reduction in the inhospital mortality, a 37% reduction in 
pneumonia-related mortality, a 77% reduction in bacteremia-
related mortality, a 60% reduction in sepsis-related mortality, 
and a 50% reduction in mixed infection-related mortality.105 
Dobesh et al106 retrospectively assessed the link between 
statin therapy and severe sepsis in 188 intensive care unit 
patients and found a 35% reduction (P = 0.04) compared 
with nonusers having APACHE II scores of $24. Finally, 
statins have been associated with reduced mortality in 
solid-organ transplant recipients who developed bacteremia107 
and a decreased risk of Candida infection in hospitalized 
diabetics (P = 0.031),108 indicating that statins may be ben-
eficial in immunocompromised patients or those at risk for 
  opportunistic infections (Table 6).
Conclusion
The major limitations regarding the current literature on the 
pleiotropic effects of statins are that the majority of studies 
were observational in nature, and usually small in size. 
There is a lack of data corroboration via large, randomized, 
placebo-controlled trials. While current evidence is not 
definitive, there is great potential for the use of statins as 
adjuvant therapy in a wide range of disease processes and is 
a worthwhile topic for researchers and clinicians alike.
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